2022
Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma
Kim E, Jiang Y, Xu T, Bazeos A, Knapp A, Bolen C, Humphrey K, Nielsen T, Penuel E, Paulson J. Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma. BMC Cancer 2022, 22: 231. PMID: 35236331, PMCID: PMC8892802, DOI: 10.1186/s12885-022-09237-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicEnhancer of Zeste Homolog 2 ProteinExome SequencingFemaleHumansLymphoma, Large B-Cell, DiffuseMaleMiddle AgedMutationPrognosisProto-Oncogene Proteins c-bcl-2RNA-SeqSulfonamidesTreatment OutcomeConceptsSequence dataWhole-exome sequencing dataExome-sequencing dataTargeted sequencing platformsExome sequencing dataTargeted sequencing dataBackgroundDiffuse large B-cell lymphomaLarge B-cell lymphomaSequencing platformsRNA-seqDe novo DLBCLImproved overall survivalTarget sequenceB-cell lymphomaVenetoclax therapyMutation subtypesPrognostic subsetsMutationsOverall survivalMolecular subsetsSubset distributionMutation groupSurvival outcomesMutation profilesClinical associations
2020
Lymphoma Microenvironment Deconvolution Links M1 Macrophage Infiltration to Clinical Outcome in Diffuse Large B-Cell Lymphoma
Yan M, Chang Y, Raghavan V, Dong E, Klein C, Nielsen T, Paulson J, Hatzi K. Lymphoma Microenvironment Deconvolution Links M1 Macrophage Infiltration to Clinical Outcome in Diffuse Large B-Cell Lymphoma. Blood 2020, 136: 29-30. DOI: 10.1182/blood-2020-134867.Peer-Reviewed Original ResearchProgrammed death-ligand 1Current equity holderMacrophage infiltrationM1 macrophagesF. Hoffmann-La RocheLymphoma microenvironmentMacrophage scoreMacrophage signatureClinical outcomesProgrammed death-ligand 1 mRNA expressionDiffuse large B-cell lymphomaNatural killer (NK) cellsAssociated with shorter PFSCD20-targeted monoclonal antibodyNK cell-mediated ADCCPrognostic trendTreatment outcomesLarge B-cell lymphomaRecruitment of M1 macrophagesPhase III clinical trialsImmune microenvironment profilesInternational Prognostic IndexResponse to immunochemotherapyDeath-ligand 1Improved overall survival